Magnesium for neuroprotection in birth asphyxia

Drugs for neuroprotection after birth asphyxia: Pharmacologic adjuncts to hypothermia.

An adverse outcome is still encountered in 45% of full-term neonates with perinatal asphyxia who are treated with moderate hypothermia. At present pharmacologic therapies are developed to be added to hypothermia. In the present article, these potential neuroprotective interventions are described based on the molecular pathways set in motion during fetal hypoxia and following reoxygenation and r...

Antenatal magnesium sulfate for neuroprotection before preterm birth?

Preterm infants are at increased risk for serious, lifelong neurologic abnormalities such as cerebral palsy.1,2 As the survival of preterm infants has improved with advances in perinatal care,2 the occurrence of cerebral palsy has increased further, since infants who would previously have died now survive with their cerebral pathology. Currently, more than 30% of children with cerebral palsy ar...

Birth asphyxia.

Update on the use of magnesium sulphate for fetal neuroprotection in preterm birth.

The administration of magnesium sulphate to mothers at risk for preterm birth for fetal neuroprotection has demonstrated to reduce the risk of cerebral palsy and gross motor dysfunction by 30-40%. Although there is controversy regarding the regimen of administration of magnesium sulphate, the gestational age limit, the extent of its potential benefit or even if it provides any benefit, current ...

Different magnesium sulphate regimens for neuroprotection of the fetus for women at risk of preterm birth.

BACKGROUND The effectiveness of antenatal magnesium sulphate for neuroprotection of the fetus, infant, and child prior to very preterm birth, when given to women considered at risk of preterm birth, has been established. There is currently no consensus as to the regimen to use in terms of the dose, duration, the use of repeat dosing and timing. OBJECTIVES To assess the comparative effectivene...